Related Experiment Videos
Prodrugs in genetic chemoradiotherapy
Adam V Patterson1, Mark P Saunders, Olga Greco
1Auckland Cancer Society Research Center, Private Bag 92019, University of Auckland, New Zealand. a.patterson@auckland.ac.nz
Current Pharmaceutical Design
|October 8, 2003
Summary
Gene-Directed Enzyme-Prodrug Therapy (GDEPT) enhances cancer treatment by combining gene therapy with radiation. This approach uses prodrugs activated by enzymes in modified cells to kill nearby cancer cells, improving radiotherapy outcomes.
Area of Science:
- Oncology
- Gene Therapy
- Radiotherapy
Background:
- Concurrent gene therapy and radiotherapy offer a promising strategy for solid tumor management.
- Gene-Directed Enzyme-Prodrug Therapy (GDEPT) is appealing as it complements existing chemoradiation protocols.
Purpose of the Study:
- To review prodrugs used in GDEPT, focusing on their translational research and clinical utility in combination with radiotherapy.
- To highlight the importance of the bystander effect and efficient metabolite diffusion for radiosensitization.
Main Methods:
- Review of various prodrugs and their corresponding activating enzymes used in GDEPT.
- Analysis of GDEPT approaches in combination with radiotherapy.
- Discussion of prodrugs with and without established chemotherapeutic counterparts.
Main Results:
- Several prodrugs, including 5-fluorocytosine, cyclophosphamide, and gemcitabine, are suitable for combination with radiotherapy.
- GDEPT strategies like ganciclovir/HSV-tk and E. coli nitroreductase have been explored but lack direct clinical chemotherapeutic counterparts.
Conclusions:
- GDEPT holds significant potential for improving radiotherapeutic management of solid tumors.
- Efficient bystander effects and prodrug metabolite diffusion are crucial for successful radiosensitization in combined GDEPT and radiotherapy approaches.